在ocrelizumab治疗中出现严重症状晚发性中性的复发
Ysoline Beigneux1, Celine Louapre1, Kevin Bihan2
1Sorbonne University, Paris Brain Institute - ICM, Assistance Publique Hôpitaux de Paris, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, France.
概括
晚发性中性 (LON) 是ocrelizumab的一个罕见的副作用. 在三名患者中出现了复发性症状性亚核细胞瘤,这表明在第一个LON插曲后,建议在治疗中切换治疗.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 晚发性中性 (LON) 是一种罕见的不良事件,与像ocrelizumab这样的抗CD20疗法有关.
- 在治疗后4周至6个月期间,绝对中性粒细胞数 (ANC) 的下降是LON的特征.
- 由于ocrelizumab诱导的LON复发的风险在很大程度上仍然没有特征.
研究的目的:
- 研究用ocrelizumab治疗的患者中反复发生的中性缺血的发生和影响.
- 为了突出严重中性衰竭的潜力,特别是亚核细胞瘤,在治疗ocrelizumab后.
主要方法:
- 一系列病例报告了三例复发性症状性农核细胞瘤.
- 分析奥克雷利祖马布 (ocrelizumab) 给药和中性衰竭发展后的患者数据.
主要成果:
- 三名患者出现了复发性症状性亚核细胞瘤 (ANC < 500/mm3) 的症状.
- 这些事件发生在ocrelizumab治疗期间,表明复发的可能性.
结论:
- 症状性亚核细胞瘤瘤的复发是与ocrelizumab相关的重大风险.
- 由于LON的复发风险,在LON的初始发作后应考虑其他治疗方案.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Immunodeficiency Diseases
957
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
957
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
170
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
170
Disorders of Leukocytes
965
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
965
Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Chronic Kidney Disease II: Clinical Manifestations
12
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
12


